Form 4: Director John T. Henderson Increases Cytokinetics Stake
Statement of Changes in Beneficial Ownership
Director John T. Henderson acquired 2,851 shares of common stock and 4,301 stock options in Cytokinetics Inc.
Summary
- Director John T. Henderson acquired 2,851 shares of common stock at a price of $0, representing a grant or award.
- The director also received 4,301 non-qualified stock options with an exercise price of $77.15.
- Following these transactions, the director's direct beneficial ownership of common stock increased to 78,088 shares.
- The director maintains an indirect interest of 83 shares held by a spouse.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, routine disclosure of director equity compensation that does not signal a change in company strategy or financial health.
Positives
- Increased alignment between director and shareholder interests through additional equity acquisition.
- Director continues to maintain a significant direct ownership position in the company.
Negatives
- None identified in this filing.
Risks
- Stock options are subject to market volatility and may not reach the exercise price of $77.15.
Future Outlook
The filing does not provide forward-looking guidance regarding company performance, focusing solely on director equity changes.
Industry Context
StockSavvy.ai notes that director equity grants are standard practice in the biotechnology sector to ensure long-term alignment with corporate milestones and shareholder value creation.
Comparison to Industry Standards
- The acquisition of equity by directors is consistent with standard corporate governance practices for mid-cap biopharmaceutical companies.
- The use of non-qualified stock options as part of director compensation is a common industry practice to incentivize long-term performance.
Stakeholder Impact
- Positive signal to shareholders regarding director commitment to the company's future.
Next Steps
- Options become exercisable on 06/27/2026.
Key Dates
| Date | Description |
|---|---|
| 05/27/2026 | Date of the reported transactions and filing date. |
| 06/27/2026 | Date the stock options become exercisable. |
| 05/26/2036 | Expiration date of the stock options. |
Keywords
Cytokinetics, CYTK, Insider Trading, Form 4, Director Ownership, Stock Options
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.